A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

MLA

Moore, Kathleen N., et al. “A Phase 1b Dose Escalation Study of Ipafricept (OMP54F28) in Combination with Paclitaxel and Carboplatin in Patients with Recurrent Platinum-Sensitive Ovarian Cancer.” Gynecologic Oncology, vol. 154, no. 2, Aug. 2019, pp. 294–301. EBSCOhost, https://doi.org/10.1016/j.ygyno.2019.04.001.

APA

Moore, K. N., Gunderson, C. C., Sabbatini, P., McMeekin, D. S., Mantia-Smaldone, G., Burger, R. A., Morgan, M. A., Kapoun, A. M., Brachmann, R. K., Stagg, R., Farooki, A., & O’Cearbhaill, R. E. (2019). A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology, 154(2), 294–301. https://doi.org/10.1016/j.ygyno.2019.04.001

Chicago

Moore, Kathleen N, Camille C Gunderson, Paul Sabbatini, D Scott McMeekin, Gina Mantia-Smaldone, Robert A Burger, Mark A Morgan, et al. 2019. “A Phase 1b Dose Escalation Study of Ipafricept (OMP54F28) in Combination with Paclitaxel and Carboplatin in Patients with Recurrent Platinum-Sensitive Ovarian Cancer.” Gynecologic Oncology 154 (2): 294–301. doi:10.1016/j.ygyno.2019.04.001.